RESULTS: 35 patients were identified (26 men and 9 women). Indications are shown in Table 1 . On initial video-urodynamic studies 20/35 (57%) had non-compliant bladder, with an average end fill pressure of 37 cmH2O (range 12-80cmH2O), a further 12/35 (31.4%) had early onset DO from an average of 133mls (range 49-220mls) with incontinence making compliance difficult to assess. 3 patients had end fill detrusor overactivity, with only 2 patients having normal compliance.
INTRODUCTION AND OBJECTIVES: OnabotulinumtoxinA (onabotA) has been shown to improve urinary symptoms and quality of life in patients with overactive bladder (OAB) in randomized, placebocontrolled trials. These trials have also reported an increase in incidence of urinary retention after onabotA treatment. Comparable data in everyday clinical practice are limited. Here, we present the results of a large, first of its kind, prospective, observational, multinational study of onabotA as a treatment for OAB performed in a real-world setting.
METHODS: Patients aged !18 years with OAB and urinary incontinence (UI) inadequately managed with an anticholinergic received onabotA per physicians' normal clinical practice. Posttreatment efficacy assessments reported here were performed at weeks 1 and/or 12 and included mean change from baseline (BL) in number of UI episodes/day, and number of nocturia, urgency, and micturition episodes/day. Reinjection was based on patient request or physician judgment. Adverse events (AEs) and adverse drug reactions (ADRs, related to treatment) including urinary retention, throughout the first treatment cycle (up to 12 months post-treatment in patients prior to, or not receiving, retreatment) were also recorded.
RESULTS: This European multinational study was performed in 4 countries. At BL mean age was 63.3 years and 84.9% of the population were women. ADRs of urinary retention were reported in 5/504 patients (1.0%) throughout the first treatment cycle. A significant reduction was observed in UI frequency post-treatment. The change in UI episodes/day from 12.0 at BL was -5.6 (P<.001) at week 1 and -7.8 (P<.001) at week 12. Similarly, the number of daily nocturia, urgency, and micturition episodes were also significantly reduced from BL at weeks 1 and 12 (all P<.001). In total, 122 patients received retreatment with onabotA; on average 281 days after the first treatment. Throughout the first treatment cycle a total of 57 AEs were reported in 38 patients (7.5%); 9 experienced serious AEs. Overall, 17 ADRs (all non-serious) were reported by 13/504 (2.6%) patients; 7 reported mild ADRs, 5 moderate, and 1 severe. Urinary tract infection was reported in 2 patients (0.4%).
CONCLUSIONS: In this real-world study in patients with OAB, improvements in urinary symptoms with onabotA were sustained for at least 12 weeks and were associated with a lower incidence of urinary retention than reported in prior phase 3 and 4 trials. No new safety signals related to onabotA were identified.
Source of Funding: Allergan plc.
PD65-08 POOR SLEEP QUALITY IS ASSOCIATED WITH CLINICALLY SIGNIFICANT LOWER URINARY TRACT SYMPTOMS
Jenna Bates*, Houston, TX; Taylor Kohn, Baltimore, MD; Katherine Rodriguez, Houston, TX; John Sigalos, Los Angelos, CA; Asad Hasan, Houston, TX; Alexander Pastuszak, Salt Lake City, UT; Larry Lipshultz, Houston, TX INTRODUCTION AND OBJECTIVES: Increasingly, poor sleep is associated with poor health. Few studies have assessed the impact of sleep quality, sleep apnea, and sleep hygiene on lower urinary tract symptoms (LUTS). Here we utilize three validated sleep questionnaires to assess the relationship between sleep and LUTS.
METHODS: Men presenting to a single academic andrology clinic between July 2017 and November 2017 completed the validated International Prostate Symptom Score (IPSS), Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index, and STOP-BANG (to assess risk of sleep apnea) questionnaires. Patients were asked about comorbidities, smoking, shift work status, body mass index (BMI), daily caffeine intake, and medication use. We performed multiple linear regressions to assess the relationship between sleep and IPSS score while controlling for age, BMI, burden of comorbidity, caffeine intake, melatonin and other sleep medication use, continuous positive airway pressure (CPAP) device use, shift work, smoking, depression status, and antidepressant use.
RESULTS: In all, 377 men were included in this study with a mean(SD) age of 46.1(13.2) years and mean(SD) BMI of 30.0(4.6). On regression analysis, men had worse LUTS as global sleep quality decreased, as measured using the PSQI. For each point increase in PSQI score, indicating worse sleep, IPSS score increased by 0.62 points, indicating worse lower urinary tract function (p<0.0001). Men with "very bad sleep" according to the PSQI had IPSS scores 4 points higher than men with "fairly bad sleep," 7 points higher than those with "fairly good sleep," and 10 points higher than those with "very good sleep." Men who were at high risk for sleep apnea had IPSS scores 3.2 points higher than men at low risk (p [ 0.008), while the use of CPAP was associated with a 2.8 point increase in IPSS score (p [ 0.045). Importantly, improved sleep hygiene was associated with significant improvement in IPSS scores (p [ 0.03). Older age was associated with worse IPSS scores in all regression models (p < 0.001).
